Results 51 to 60 of about 4,697 (156)

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies

, 2021
Bruton tyrosine kinase (BTK) inhibition is an effective therapy for many B-cell malignancies. Acalabrutinib is a next-generation, potent, highly selective, covalent BTK inhibitor.
Owen, Roger G, Pagel, John M, Stephens, Deborah M., Streetly, Matthew J, Obrien, Susan M., Byrd, John C, Owen, Roger G., O\u27Brien, Susan M, Jurczak, Wojciech, Hamdy, Ahmed M, Furman, Richard R, Hillmen, Peter, Baek, Marshall, Pagel, John M., Furman, Richard R., Dyer, Martin J S, Stephens, Deborah M, Streetly, Matthew J., Sharman, Jeff P., Lezhava, Tamara, Patel, Priti, Sharman, Jeff P, Brown, Jennifer R, Christian, Beth, Dyer, Martin J. S., Sun, Clare, Chernyukhin, Nataliya, Brown, Jennifer R., Byrd, John C., Rule, Simon, Wang, Michael, Izumi, Raquel, Hamdy, Ahmed M., Ghia, Paolo   +33 more
core   +2 more sources

Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC)

Therapeutic Advances in Medical Oncology
Background: There are no head-to-head studies comparing the efficacy of the Bruton tyrosine kinase inhibitors, zanubrutinib and acalabrutinib, in relapsed or refractory chronic lymphocytic leukemia (R/R CLL).
Mazyar Shadman, Jennifer R. Brown, Rhys Williams, Leyla Mohseninejad, Keri Yang, Pal Rakonczai, Nicole Lamanna, Sheng Xu, Aileen Cleary Cohen, Susan M. O’Brien, Alessandra Tedeschi, Constantine S. Tam   +11 more
doaj   +1 more source

Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results

Blood Advances
: Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib (ibr) revolutionized chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treatment, although treatment-related toxicities limit the use of some BTK inhibitors.
Mazyar Shadman, John M. Burke, Jennifer Cultrera, Habte A. Yimer, Syed F. Zafar, Jamal Misleh, Subramanya S. Rao, Charles M. Farber, Aileen Cohen, Hui Yao, Adam Idoine, Qi An, Ian W. Flinn, Jeff P. Sharman   +13 more
doaj   +1 more source

Economic Burden of Chronic Lymphocytic Leukaemia in Australia

European Journal of Haematology, EarlyView.
ABSTRACT Background The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia. Methods A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in ...
Lan Gao, Dieu Nguyen, Victoria White, Patricia M. Livingston, Chan Y. Cheah   +4 more
wiley   +1 more source

A guide to transcriptional cyclin‐dependent kinases in cancer

The FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin, Salla Kyheröinen, Ricky W. Johnstone   +2 more
wiley   +1 more source

Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.
ABSTRACT Background Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.
Grietje van Elp, Maikel Borg, Jens H. J. Bos, Catharina C. M. Schuiling‐Veninga, Katja Taxis, Frank G. A. Jansman   +5 more
wiley   +1 more source

Process for the Preparation of Crystalline Acalabrutinib Maleate Monohydrate [PDF]

Process for the Preparation of Crystalline Acalabrutinib Maleate Monohydrate Acalabrutinib or 4-{8-Amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1- yl}-N-(pyridin-2-yl)benzamide is the active pharmaceutical ingredient (API) in the ...
Anonymous,
core   +1 more source

Expert Opinion on Managing Adverse Reactions Associated With Acalabrutinib Therapy: A Delphi Consensus From France

International audienceAcalabr utinib, a second-generation Br uton's tyrosine kinase inhibitor (BTKi), offers an improved safety profile compared to first-generation inhibitors like ibrutinib.
Ederhy, Stéphane, Leblond, Véronique, Malartre, Stéphanie, Sibaud, Vincent, Ysebaert, Loïc, Portalier, Anaïs, Zerbit, Jérémie, Tomowiak, Cécile   +7 more
core   +1 more source

Extranodal Organ Involvement in Chronic Lymphocytic Leukemia: Clinical Features and Outcomes With Bruton Tyrosine Kinase and BCL‐2 Inhibitors

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Background Although chronic lymphocytic leukemia (CLL) typically follows an indolent course involving blood, lymph nodes, and bone marrow, extranodal organ involvement is rare and poorly characterized. Methods We retrospectively analyzed 19 patients with histologically confirmed extranodal CLL or small lymphocytic lymphoma (SLL), assessing ...
Finn J. Schulze, Evgenii Shumilov, Akhil Behringer, Andrea Kerkhoff, Matthias Eckhardt, Simone Bätker, Markus Maulhardt, Georg Lenz, Alexander Pohlmann   +8 more
wiley   +1 more source